Indications and Medication Guide for Lenvatinib (Lenvatinib, Lenvima)

Lenvatinib (Lenvatinib, Lenvima), as a multi-target kinase inhibitor, has demonstrated excellent efficacy and safety in cancer treatment. In order to allow patients to have a more in-depth understanding of and rational use of this drug, this article will elaborate on the applicable objects and correct medication methods of lenvatinib.

1. Applicable objects

Lenvatinib is mainly suitable for patients with the following types of cancer:

1. Differentiated thyroid cancer(DTC): For patients with local recurrence or metastasis, progressive disease, and refractory to radioactive iodine, lenvatinib provides a new treatment approach.

2. Advanced renal cell carcinoma(RCC): Adult patients can choose lenvatinib in combination with pembrolizumab as first-line treatment, or in combination with everolimus if they have previously received anti-angiogenic therapy.

3. Unresectable hepatocellular carcinoma(HCC): As a first-line treatment for these patients, lenvatinib provides an effective treatment.

4. Advanced endometrial cancer (EC): For patients with non-microsatellite instability high (MSI-H) or mismatch repair deficiency (dMMR) whose disease has progressed after systemic therapy and are not suitable for surgery or radiotherapy, the combination of lenvatinib and pembrolizumab brings new hope.

2. Medication Guide

The use of lenvatinib needs to be based on the patient’s specific conditions and doctor’s guidance:

1. Monotherapy:

1) DTC patients: The recommended dose is 24 mg, taken orally once daily.

2) HCC patients: Based on the actual weight, patients greater than or equal to 60kg should take 12mg orally once a day, and patients less than 60kg should take 8mg orally once a day.

2. Combined treatment:

1) EC patients: When used in combination with pembrolizumab, the recommended dose is 20 mg orally once daily.

2) RCC patients: When combined with pembrolizumab, the recommended dose of lenvatinib is 20 mg orally once a day; when combined with everolimus, the recommended dose is 18 mg orally once a day.

3. Special patients:

For patients with renal or hepatic impairment, the daily dose may need to be adjusted as directed by your physician.

4. Administration method:

1) Lenvatinib should be taken orally at a fixed time every day, on an empty stomach or with food.

2) The medicine should be swallowed whole. If it is difficult to swallow, it can be mixed with a tablespoon of water or apple juice before taking.

3) If you miss a dose and cannot take it again within 12 hours, there is no need to take the next dose at the regular time.

In summary, lenvatinib provides a new treatment option for patients with various cancers. During use, patients should strictly follow the doctor's instructions and adjust the medication plan according to the specific situation to ensure treatment effect and medication safety.